Mirador Biomedical Inc.
Reducing risk in central venous access
This article was originally published in Start Up
During insertion of central venous catheters, physicians may unintentionally advance into an artery rather than the desired vein, an error that can cause serious complications, even death. Mirador Biomedical Inc. aims to improve the safety of central venous access with its Compass platform, battery-powered, pressure-measurement devices that can rapidly detect the difference in pressures between arteries and veins.
You may also be interested in...
Formal dispute resolution was key element in four-month turnaround from rejection by US FDA to approval for golodirsen, the second Sarepta DMD drug to clear the agency after appearing to have minimal prospects.
Correvio’s attempt to move vernakalant from 'clinical hold' to 'FDA approved' was a huge long shot. But the advisory committee vote – and looming FDA rejection – are another indication that real-world data is not a panacea.